Uniform Graft-versus-Host Disease Prophylaxis using Post-Transplantation Cyclophosphamide, Methotrexate, and Cyclosporine following Peripheral Blood Hematopoietic Stem Cell Transplantation from Matched and Haploidentical Donors for Transfusion-Dependent Thalassemia: A Retrospective Report from the Bone Marrow Failure Working Group of Hunan Province, China

Gong, Susu; Tian, Xin; Yang, Rui; Yang, Liangchun; Wang, Zhiming; Yang, Kaitai; Chen, Keke; He, Xianglin; Deng, Wenjun; Yang, Xiaoyang; Lei, Meiqing; Fu, Bin

doi:10.1016/j.jtct.2024.08.022

Transplantation and Cellular Therapy

2024

DOI: 10.1016/j.jtct.2024.08.022

|View full text |Cite

Uniform Graft-versus-Host Disease Prophylaxis using Post-Transplantation Cyclophosphamide, Methotrexate, and Cyclosporine following Peripheral Blood Hematopoietic Stem Cell Transplantation from Matched and Haploidentical Donors for Transfusion-Dependent Thalassemia: A Retrospective Report from the Bone Marrow Failure Working Group of Hunan Province, China

Susu Gong,

Xin Tian,

Rui Yang

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Allogeneic Stem Cell Transplantation in the Treatment for Transfusion-Dependent Thalassemia: Centre Experience

Pivkova-Veljanovska,

Chadievski,

Kocoski

et al. 2024

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Allogeneic stem cell transplantation (allo SCT) is still the only curative option for transfusion depended on β-thalassemia major (TDT). In patients with good risk features it is reasonable to anticipate a greater than 90% chance of a successful transplant outcome. With better risk stratification and supportive care, the results of allo-SCT have been improved even in high risk patients who have significant iron overload related organ dysfunction. Choosing the optimal conditioning regimen before allo SCT, stem cell source and focusing on transfusion free survival, as well as graft versus host disease (GVHD) free survival is a challenge in providing the quality of life in the post-transplant period for this indication. The aim of this article is to present first experience in the treatment of TDT with allo SCT from matched related donor (MRD). CASE PRESENTATION: We present a case of male patient diagnosed as thalassemia major (TM) at the age of 15 years referred at University Clinic for pediatric disease in Skopje, Republic of North Macedonia for treatment with allogeneic stem cell transplantation (allo SCT) from matched related family donor (MRD). Patients experienced two allo SCT due to early graft rejection after the first transplantation. The conditioning was done with MAC regimens, busulfan based for the first transplant and treosulfan based for the second transplant. CONCLUSION: Disease severity and the age of the patient has a crucial impact on transplant related mortality (TRM), event free survival (EFS) and the incidence of veno-oclusive liver disease as one of the main complications during SCT. More data is required on the etiology of frequent graft rejection in TDT studying the aspects of the graft and subsequent immune reconstitution that can improve the outcome of allo HSCT for thalassemia major.

show abstract

Allogeneic Stem Cell Transplantation in the Treatment for Transfusion-Dependent Thalassemia: Centre Experience

Pivkova-Veljanovska,

Chadievski,

Kocoski

et al. 2024

Open Access Maced J Med Sci

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Cited by 1 publication

References 29 publications

Allogeneic Stem Cell Transplantation in the Treatment for Transfusion-Dependent Thalassemia: Centre Experience

Allogeneic Stem Cell Transplantation in the Treatment for Transfusion-Dependent Thalassemia: Centre Experience

Contact Info

Product

Resources

About